Mylan Crohn's Drug Doesn't Infringe AstraZeneca IP: Judge
A Delaware federal judge on Thursday ruled that Mylan Inc.'s generic version of Crohn's disease medication Entocort EC did not infringe a patent held by AstraZeneca Pharmaceuticals LP....To view the full article, register now.
Already a subscriber? Click here to view full article